Clinical trial
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00268216 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00268216 |
|---|---|
| Title | Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Salmeterol 50mcg/ Fluticasone Propionate 500mcg |
| Enrollment | 6,228 |
| Start date | Sep 1, 2000 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Dec 22, 2005 |
| Last update posted | Jan 20, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark and 32 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: